erlotinib hydrochloride has been researched along with Cardiac Failure in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ieda, M; Nagashio, K; Sato, K; Tajiri, K | 1 |
| Gu, M; Hong, X; Liang, J; Lu, C; Sun, X; Tang, J; Wang, X; Xu, W; Yao, X; Zhong, T | 1 |
| Branca, MA | 1 |
3 other study(ies) available for erlotinib hydrochloride and Cardiac Failure
| Article | Year |
|---|---|
Erlotinib-Induced Cardiomyopathy in a Patient with Metastatic Non-Small Cell Lung Cancer.
Topics: Aged; Biopsy; Carcinoma, Non-Small-Cell Lung; Cardiomyopathies; Cardiotoxicity; Disease Progression; Dyspnea; Erlotinib Hydrochloride; Female; Follow-Up Studies; Heart Failure; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors | 2021 |
The activation of EGFR promotes myocardial tumor necrosis factor-α production and cardiac failure in endotoxemia.
Topics: Animals; Endotoxemia; ErbB Receptors; Erlotinib Hydrochloride; Heart Failure; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Phosphorylation; Quinazolines; Signal Transduction; Tumor Necrosis Factor-alpha | 2015 |
BiDil raises questions about race as a marker.
Topics: Biomarkers; Black People; Clinical Trials as Topic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Drug Approval; Drug Combinations; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Heart Failure; Humans; Hydralazine; Isosorbide; Middle Aged; Mutation; National Institutes of Health (U.S.); Polymorphism, Genetic; Quinazolines; Risk Factors; Socioeconomic Factors; Treatment Outcome; United States; Uracil; White People | 2005 |